DIMETANE-DX
LOE Approachingbrompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride
NDAORALSYRUP
Approved
Aug 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DIMETANE-DX (brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride) is clinical pharmacology brompheniramine maleate is a histamine antagonist, specifically an h 1 -receptor-blocking agent belonging to the alkylamine class of antihistamines. Approved for nasal congestion due to the common cold, hay fever, other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy and 2 more indications. First approved in 1984.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIMETANE-DX is an oral syrup combination containing brompheniramine maleate (H1-receptor antagonist), dextromethorphan hydrobromide (antitussive), and pseudoephedrine hydrochloride (decongestant). It treats nasal congestion, cough, and allergy symptoms associated with the common cold, hay fever, and upper respiratory allergies by blocking histamine receptors, suppressing cough reflex, and causing vasoconstriction of nasal blood vessels.
LOE Approaching
Product is nearing end-of-life with moderate competitive pressure (30%), suggesting smaller brand teams focused on maximizing remaining patent value before generic competition intensifies.
Mechanism of Action
CLINICAL PHARMACOLOGY Brompheniramine maleate is a histamine antagonist, specifically an H 1 -receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic…
Indications (5)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.